Poster Discussion  

Session/Topic: Clinical HIV

<table>
<thead>
<tr>
<th>N.</th>
<th>Title:</th>
</tr>
</thead>
<tbody>
<tr>
<td>PD 7</td>
<td>Health status and Quality of life in people living with HIV (PLWH): results from the ICONA cohort</td>
</tr>
</tbody>
</table>

Authors:
A. Cingolani, J. Romaine, A. Tavelli, F. Maggiolo, E. Girardi, A. Antinori, A. Cascio, A.M. Cattelan, A. De Luca, M. Murray, A. d’Arminio Monforte, A. Bradley for ICONA Foundation study Group

Affiliation:
1Catholic University, Roma, Italy, 2Health Psychology Research Unit, University of London, London, UK, 3Icona Foundation, Milano, Italy, 4Azienda Ospedaliera S. Giovanni XXIII, Bergamo, Italy, 5National Institute for Infectious Diseases "L. Spallanzani", Roma, Italy, 6AOU Policlinico "P. Giaccone", Palermo, Italy, 7Azienda Ospedaliera Padova, Padova, Italy, 8University of Siena, Siena, Italy, 9ViiV Healthcare, London, United Kingdom, 10University of Milano, Milano, Italy, 11Health Psychology Research, Ltd, University of London, London, Italy

Abstract:
**Background:** As HIV has become a long-term condition, it is important to evaluate the impact of therapies on patients’ Quality of Life (QoL) and other Patient-Reported Outcomes (PROs). ICONA is investigating several PROs including QoL (generic and HIV-specific), health status, symptoms, well-being and treatment satisfaction. Here we report preliminary analyses of associations between clinical/demographic variables and health status and QoL in PLWH, enrolled in ICONA.

**Methods:** The HIV-Dependent QoL (HIVDQoL) and EQ-5D-3L health-status tool were administered consecutively to two groups of ICONA patients from March 2017 to March 2018. Patients enrolled were, newly diagnosed, pre-treatment patients, and those with >6 months of cART. These preliminary analyses focused on the HIVDQoL overview item measuring generic QoL (3=’excellent’ to -3=’extremely bad’) and the EQ-5D visual analogue score (EQ-VAS) measuring self-rated health from (100=’best imaginable health state’ to 0=’worst’). Analyses included non-parametric tests of difference and correlational analyses.

**Results:** The total sample (N=135) included 122 men and 13 women, mean age 43 (SD: 12.25). 107 patients were on cART (NNSTI: N=66, NNRTI: N=23, PI: N=15/r-based regimen), 28 provided data pretreatment. Mode of transmission included: MSM (N=76), heterosexual (N=40) and IDU (N=10). Mean CD4+ was 655/mmc (SD:316) for those on cART and 429/mmc (SD:259) for patients pretreatment. Mean self-reported health (EQ-VAS) was 79 (SD: 14.57) for cART-treated and 78 (SD:18.73) for those pretreatment. Generic QoL (HIVDQoL item 1) mean was 1.21 (SD:1.19) (>’good’ QoL) for cART-treated and 0.48 (SD:1.74) (midway between ’neither good nor bad’ and ’good’) for those pretreatment. EQ-VAS health scores were found to differ by mode of transmission, with MSM reporting better health than IDU (p=0.022) and those reporting heterosexual transmission (p=0.043). However, there was no difference in QoL by mode of transmission. Treatment with cART was associated with better QoL than pretreatment status (p=0.049), with no differences in health ratings. QoL, but not health status, was significantly worse for patients with a CD4 count of <200 than those with a CD4 count of 200-499 (p=0.035) or CD4 count >=500 (p=0.037). Correlational analyses for cART-treated patients, showed age was negatively related to both QoL (-0.312, p=0.001) and health (-0.357, p<0.001).

**Conclusion:** Although both generic QoL and health status were worse in older (vs younger) people living with HIV, the two outcomes showed different patterns in relation to clinical variables, with cART-treated patients reporting better QoL but no difference in perceived health compared with pretreatment patients. QoL, but not perceived health, was also better in patients with CD4 counts >200. Perceived health, but not QoL, differed with mode of HIV transmission. QoL is not simply a reflection of health status and it is important to measure both outcomes.

This study is supported by a grant from ViiV Healthcare.